Fidelity Advisor Biotechnology C holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Fidelity Advisor Biotechnology Fund - Class C FBTCX
- NAV / 1-Day Return 34.99 / −0.03 %
- Total Assets 2.4B
-
Adj. Expense Ratio
1.690%
- Expense Ratio 1.690%
- Distribution Fee Level Low
- Share Class Type Level Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 0
- Status Open
- TTM Yield 1.08%
- Turnover 54%
USD | NAV as of Oct 03, 2026 | 1-Day Return as of Oct 03, 2026, 12:11 AM GMT+0
Morningstar’s Analysis FBTCX
Will FBTCX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 46.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
AbbVie Inc | 14.71 | 324M | Healthcare |
Gilead Sciences Inc | 5.70 | 125M | Healthcare |
Spyre Therapeutics Inc | 3.83 | 84M | Healthcare |
Alnylam Pharmaceuticals Inc | 3.62 | 80M | Healthcare |
Dianthus Therapeutics Inc | 3.55 | 78M | Healthcare |
Cogent Biosciences Inc | 3.25 | 71M | Healthcare |
Oruka Therapeutics Inc | 3.24 | 71M | Healthcare |
Insmed Inc | 3.05 | 67M | Healthcare |
Revolution Medicines Inc Ordinary Shares | 3.00 | 66M | Healthcare |
argenx SE ADR | 3.00 | 66M | Healthcare |
United States